Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ICM20

Phase 1Small molecule

IIC-MedTech Corporation

ICM20 is one of 28 small molecule programs targeting Phase 1. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

27

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase 1Active, not recruiting

Phase 1Phase 1

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Phase 1

#DrugCompanyPhaseTrials

Venclexta

Cytoxan

BBaxter Healthcare Corporation

Erbitux

Rayos

RRoxane Laboratories

Navitoclax

Fludara

Yervoy

Bristol-Myers Squibb

Benznidazole

CCorestemchemon, Inc.

VX-407

Vertex Pharmaceuticals

Radiprodil

GGRIN Therapeutics, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Phase 1

NCT05523596

Clinical

Trials by Indication[1]

Phase 11 trial

A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

Active, not recruiting·IIC-MedTech Corporation·Phase 1·NCT05523596·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ICM20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICM20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICM20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IC-MedTech Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IIC-MedTech Corporation

Related News